ClinicalTrials.gg
Enrolling by invitationNCT05698836CHAPTERUpdated Jan 26, 2023

Cardiovascular Health Assessment of Preterm- and TERm-born Children

An observational study in Premature Birth, sponsored by University of Oxford. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 3 Years to 9 Years. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by University of Oxford · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2023, 3 years 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
3 Years to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Premature Birth by University of Oxford — 3 open to participants now, 4 under way, none of them phase 3. Premature Birth · University of Oxford.

Started
2019
the only one that year
Observational
9 of 11
3 open now
Registered
8th of 11
by date

Among the 11 studies in Premature Birth by University of Oxford, this one is the only one that started in 2019, is one of 9 observational ones, and was the 8th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

3 of the 11 studies in Premature Birth by University of Oxford are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 3 Years to 9 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Premature Birth by University of Oxford, or all of them as a file.
02

Study summary

The purpose of the CHAPTER study is to help understand how complications during pregnancy, such as preterm birth, affect how childrens' hearts and blood vessels develop.

Read the detailed description

Young adults born preterm (less than 37 weeks gestation) have alterations in the structure and function of the heart, with similar changes observed in preterm infants in the first three months of life. It is unknown whether these early changes in the heart seen in the first few months of life are relevant to long-term changes in heart structure and function. Heart changes have also not been well studied in children born preterm. To investigate this, the study will follow up children from the EPOCH study and will perform two study visits for each child (n=100 preterm and n=100 term) that will use echocardiography and cardiovascular magnetic resonance. Individuals in the EPOCH study had echocardiography measures done at birth and three months postnatal age. It will therefore be possible to do longitudinal echocardiography measures from birth up to ages 12 years to determine whether postnatal heart changes in preterm infants track into childhood. Cardiovascular magnetic resonance will allow for the determination of whether these early heart changes influence heart pump function. Finally, by measuring lung function, blood vessel structure and function, and blood pressure, it will be possible to determine how heart changes relate to other components of the cardiovascular system. This data will be used to confirm the relevance of early heart remodelling in preterm-born offspring over time and provide more comprehensive heart phenotyping for preterm-born children. Together, this information can be used to design future intervention strategies in preterm-born individuals to reduce cardiovascular risk in this growing subgroup of the population.

03

Conditions studied

  • Premature Birth

Browse trials for

Keywords

  • cardiac function
  • preterm
  • children
04

Who can participate

Ages eligible
3 Years to 9 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Children aged 3--12 years old born preterm (less than 37 weeks gestation) or term (37--42 weeks gestation) delivered at or admitted to the Oxford University Hospitals NHS Foundation Trust who took part in the EPOCH study. Recruitment also includes both siblings and friends of those who took part in the original EPOCH study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant's parent or legal guardian gives consent and the participant, where age-appropriate, gives assent for participation in the study.
  • Participant is male or female, aged 3-9 years at enrolment.
  • Participant previously took part in the EPOCH study, or the participant's friend or sibling took part.

Exclusion criteria

Exclusion Criteria:

  • Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status

For exclusion of MRI component only:

  • to MRI
  • Unsuitable for MRI based on the responses to the MRI screening form
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Cardiac left ventricular mass

    Echocardiography assessment of left ventricular mass indexed to body surface area (in g and g/m\^2)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

Secondary outcomes

  1. Cardiac right ventricular mass

    Echocardiography assessment of right ventricular mass indexed to body surface area (in g and g/m\^2)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  2. Cardiac left ventricular end-diastolic volume

    Echocardiography assessment of cardiac left ventricular end-diastolic volume indexed to body surface area (in ml and ml/m\^2)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  3. Cardiac right ventricular end-diastolic volume

    Echocardiography assessment of cardiac right ventricular end-diastolic volume indexed to body surface area (in ml and ml/m\^2)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  4. Cardiac left ventricular systolic function

    Echocardiography assessment of left ventricular systolic function: left ventricular ejection fraction (in %)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  5. Cardiac right ventricular systolic function

    Echocardiography assessment of right ventricular systolic function: tricuspid annular plane systolic excursion (in cm)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  6. Cardiac left ventricular diastolic function

    Echocardiography assessment of right ventricular (RV) diastolic function: RV Doppler early/late diastolic tricuspid inflow velocity ratio (E/A)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  7. Cardiac right ventricular diastolic function

    Echocardiography assessment of left ventricular (LV) diastolic function: LV Doppler early/late diastolic mitral inflow

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  8. Morphology of the left ventricles

    MRI assessment of the left ventricles morphology using cardiac statistical atlas and principal component analysis

    Time frame: 6-9 years of age

  9. Morphology of the right ventricles

    MRI assessment of the right ventricles morphology using cardiac statistical atlas and principal component analysis

    Time frame: 6-9 years of age

  10. Cardiac flow dynamics of the left ventricle

    MRI assessment of direct flow, delayed ejection flow, retained inflow, residual volume kinetic energy flow components at end diastole (measured at end diastole in mJ and overall % contribution)

    Time frame: 6-9 years of age

  11. Systolic blood pressure measurement

    Resting brachial blood pressure measurement (in mmHg)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  12. Diastolic blood pressure measurement

    Resting brachial blood pressure measurement (in mmHg)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  13. Mean arterial pressure

    The average arterial pressure from resting brachial blood pressure measurement (in mmHg)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  14. Retinal arteriolar structure

    Central retinal arteriolar equivalent (CRAE in μm) measured using retinal imaging

    Time frame: 6-9 years of age

  15. Retinal venular structure

    Central retinal venular equivalent (CRVE in μm) measured using retinal imaging

    Time frame: 6-9 years of age

  16. Retinal arteriolar-to-venular diameter ratio (AVR)

    The ratio of average retinal arteriolar diameter (CRAE in μm) and average retinal venous diameter (CRVE in μm) measured using retinal imaging

    Time frame: 6-9 years of age

  17. Lung function

    The forced expiratory volume in one second (FEV1 in L), forced vital capacity (FVC in L), and the ratio of FEV1 to FVC (FEV1/FVC) measured using spirometry

    Time frame: 6-9 years of age

  18. Objective measure of physical activity

    The amount of moderate to vigorous physical activity (in h/week) and vigorous physical activity (in h/week) measured using wrist worn accelerometer

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  19. Body weight

    Body weight measured in kg

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  20. Body height

    Body weight measured in m

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  21. Body mass index

    Body weight divided by the square of height (in kg/m2)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  22. Mid-arm circumference

    Mid-arm circumference measured in cm

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

  23. Waist-to-hip ratio

    The ratio of waist circumference (in cm) to hip circumference (in cm)

    Time frame: 3-5 years of age OR 8-12 years of age; AND 6-9 years of age

Other outcomes

  1. Tube formation capacity in endothelial colony forming cells (ECFCs)

    The number of closed tubes formed/1.5x10\^4 cells

    Time frame: 6-9 years of age

  2. Endothelial colony forming cells (ECFC) branches formed

    The number of branches formed/1.5x10\^4 cells

    Time frame: 6-9 years of age

  3. Endothelial colony forming cells (ECFC) colony formation

    Days for ECFC colony formation, measured in days

    Time frame: 6-9 years of age

  4. Endothelial colony forming cells (ECFC) proliferation rate

    ECFC proliferation rate, measured as a percentage

    Time frame: 6-9 years of age

  5. Subcortical brain volume of hippocampus

    Subcortical brain volume of hippocampus (in mm3) assessed on T1-weighted sequence of brain MRI

    Time frame: 6-9 years of age

  6. Subcortical brain volume of thalamus

    Subcortical brain volume of thalamus (in mm3) assessed on T1-weighted sequence of brain MRI

    Time frame: 6-9 years of age

  7. White matter hyperintensities count

    The number of white matter hyperintensities on T2-weighted sequence of brain MRI

    Time frame: 6-9 years of age

  8. White matter hyperintensities volume

    Total volume of white matter hyperintensities (in mm3) assessed on T2-weighted sequence of brain MRI

    Time frame: 6-9 years of age

  9. Cerebral vessel lumen diameter

    Cerebral vessel lumen diameter (in μm) assessed on the time-of-flight sequence of brain MRI

    Time frame: 6-9 years of age

  10. Cerebral vessel density

    Cerebral vessel density (in mm3) assessed on the time-of-flight sequence of brain MRI

    Time frame: 6-9 years of age

  11. Cerebral vessel tortuosity

    The ratio of cerebral vessel tortuosity assessed on the time-of-flight sequence of brain MRI

    Time frame: 6-9 years of age

  12. Whole brain grey matter perfusion or cerebral blood flow (CBF)

    Whole brain grey matter perfusion/CBF (in ml/100g/min) assessed on arterial spin labelling of brain MRI

    Time frame: 6-9 years of age

  13. Arterial cerebral blood volume fraction

    Arterial cerebral blood volume fraction (in %) assessed on arterial spin labelling of brain MRI

    Time frame: 6-9 years of age

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for May 2023, 50 months after the start.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 50 months is above that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Jan 26, 2023
StartActual
Mar 21, 2019
Primary completionEst.
May 31, 2023
CompletionEst.
Jun 1, 2036
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05698836
Responsible party
Sponsor
First posted
Jan 26, 2023
Start date
Mar 21, 2019
Primary completion
May 31, 2023 (estimated)
Completion
Jun 1, 2036 (estimated)
Last update
Jan 26, 2023

Study contacts

Adam Lewandowski, DPhil
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion